Sumitomo Dainippon Pharma Co Ltd's Fiscal Year is From April To March - All Figures are in JPY, Billions.
The item "End-Period-Cash-Flow" stands at 167.45 Billion Japanese Yens for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 06/30/2017.
Sumitomo Dainippon Pharma Co Ltd's second quarter result of 38.49 Billion JPY for the item "End Period Cash Flow" represents an increase of 88.19 percent compared to it's first quarter result.
Also, Sumitomo Dainippon Pharma Co Ltd's second quarter result of 38.49 Billion JPY for the item "End Period Cash Flow" represents a decrease of -61.15 percent compared to it's second quarter result of last year.
Looking again at the trailing twelve months series (TTM), Sumitomo Dainippon Pharma Co Ltd's second quarter result of 167.45 Billion JPY for the item "End Period Cash Flow" represents a decrease of -26.57 percent compared to it's first quarter result.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -31.09 percent compared to the value the year prior.
The 1 year change in percent is -31.09.
The 3 year change in percent is -81.50.
The 5 year change in percent is -65.05.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - End Period Cash Flow | 905,699,262,464.00 |
![]() | Johnson & Johnson - End Period Cash Flow | 486,508,953,600.00 |
![]() | AbbVie Inc - End Period Cash Flow | 399,570,305,024.00 |
![]() | Roche Holding AG - End Period Cash Flow | 317,433,206,677.55 |
![]() | AstraZeneca PLC - End Period Cash Flow | 280,205,508,085.11 |